Correlation Between Evolus and Medipharm Labs
Can any of the company-specific risk be diversified away by investing in both Evolus and Medipharm Labs at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Evolus and Medipharm Labs into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Evolus Inc and Medipharm Labs Corp, you can compare the effects of market volatilities on Evolus and Medipharm Labs and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Evolus with a short position of Medipharm Labs. Check out your portfolio center. Please also check ongoing floating volatility patterns of Evolus and Medipharm Labs.
Diversification Opportunities for Evolus and Medipharm Labs
0.04 | Correlation Coefficient |
Significant diversification
The 3 months correlation between Evolus and Medipharm is 0.04. Overlapping area represents the amount of risk that can be diversified away by holding Evolus Inc and Medipharm Labs Corp in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Medipharm Labs Corp and Evolus is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Evolus Inc are associated (or correlated) with Medipharm Labs. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Medipharm Labs Corp has no effect on the direction of Evolus i.e., Evolus and Medipharm Labs go up and down completely randomly.
Pair Corralation between Evolus and Medipharm Labs
Given the investment horizon of 90 days Evolus Inc is expected to under-perform the Medipharm Labs. In addition to that, Evolus is 1.1 times more volatile than Medipharm Labs Corp. It trades about -0.16 of its total potential returns per unit of risk. Medipharm Labs Corp is currently generating about -0.07 per unit of volatility. If you would invest 5.20 in Medipharm Labs Corp on September 1, 2024 and sell it today you would lose (0.40) from holding Medipharm Labs Corp or give up 7.69% of portfolio value over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Together |
| Strength | Insignificant |
| Accuracy | 100.0% |
| Values | Daily Returns |
Evolus Inc vs. Medipharm Labs Corp
Performance |
| Timeline |
| Evolus Inc |
| Medipharm Labs Corp |
Evolus and Medipharm Labs Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Evolus and Medipharm Labs
The main advantage of trading using opposite Evolus and Medipharm Labs positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Evolus position performs unexpectedly, Medipharm Labs can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Medipharm Labs will offset losses from the drop in Medipharm Labs' long position.| Evolus vs. Collegium Pharmaceutical | Evolus vs. Phibro Animal Health | Evolus vs. ANI Pharmaceuticals | Evolus vs. Procaps Group SA |
| Medipharm Labs vs. Holloman Energy Corp | Medipharm Labs vs. cbdMD Inc | Medipharm Labs vs. Evolus Inc | Medipharm Labs vs. CV Sciences |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Fundamental Analysis module to view fundamental data based on most recent published financial statements.
Other Complementary Tools
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Equity Valuation Check real value of public entities based on technical and fundamental data |